Phase 3 study of clevudine voluntarily terminated for hepatitis B

Pharmasset announced that after a discussion with its independent Data Safety Monitoring Board (DSMB) and the FDA, the company has decided to voluntarily terminate its Phase 3 QUASH studies of clevudine for the treatment of chronic hepatitis B (HBV) infection. Pharmasset recently became aware of a number of spontaneous serious adverse event reports and events of special interest (myopathy or muscle weakness associated with creatine kinase elevations) in patients receiving clevudine as prescribed therapy for hepatitis B in South Korea. Given the number and severity of cases observed in South Korea, Pharmasset concluded it was in the best interest of patients to terminate the studies at this time.

For more information call (609) 613-4100 or visit